, , ,

<<


-  >> 
Pages:   || 2 | 3 | 4 | 5 |   ...   | 9 |
-- [ 1 ] --

-

"

" V - - I V - Ż

6 - 8 2010 : .., ...

:

..,..., (. ) .., () .., ..., (.) .., ... () .., ..., () V -, IV - - !

, , . , .

, , . , , , - , , .

, , , .

, , , , , , .

I. .......................................................................................................... ., ........................................................................................ , , ..................................................... .., .., .., .., .., .................................................................................... ................................................................................................................... .., .., .., .., .. 5................................................................................................................. ......................................................................... .., .., .., .., .., ............................................................................................. :

............................................................. .., .., ..;

.., .., .., ............................................................................................................. ............................................................................................... Schulz Siegfried................................................................................................................ OZONE/OXYGEN IP IN A PRECLINICAL CANCER STUDY* WITH AN OUTLOOK IN HUMAN-AND VETERINARY MEDICINE (PILOT-RESULTS) AND OTHER PRE-CLINICAL STUDIES IN DISCUSSION TO HUMAN DISEASE ENTITIES......................................................................................................................... ...1, .., .. 1,......................................... .. 2, ...2............................................................................. -....................... .., ..................................................................................... .................................................................... .., .., ............................................................. .............................................. .., ....................................................................................... ...................................................................................................... .., .., .................................................... ......................................... Lamberto Re, M.D., Ph.D.1, 2, Gregorio Martnez-Snchez, Pharm. D., Ph.D.1......... OZONE INTERACTION WITH PAIN MEDIATORS, PRELIMINARY CLINICAL EVIDENCES.................................................................................................................... .., .., ......................................................... .................................................. .., .., .., .., .., .................................................................................................................... ................................................................................. .., .., .............................................................. - - .................................................................................................................. .., .., ......................................... IN VITRO................................................................................ .., .., ...................................................... Ļ .................................................................................................................... II. .................. .., ., .., .................... ................................................................. .., ........................................................................................ ................................................................................................................ .., .., ............................................ .......................................................................................................... .., .............................................................................................. ......................

..................................................... .., .................................................................................... ..................... .., .., ............................................ ............................................................................................................. M. Sallinen........................................................................................................................ OZONE THERAPY IN FINLAND PRELIMINARY OBSERVATIONS............... .., .., .................................................................. ...................................... - ˲Ͳ в òDz Բ - .................................................................................................................. .................................................................................................................... - .................................... .., .., .., .................................. ................................................................. ................................................................................................................ ˨ .................... .., .., ................................................................ ........................................................... Nurettin Luleci................................................................................................................ FLUOROSCOPY- GUIDED PERCUTANEOUS INTRADISCAL OZONE INJECTION.................................................................................................................... .., .., ................................................................. , , ........................................................................................................ .., ..................................................................................... ................................................................ .., .., .., ...................... ............................ .., ................................................................................ ...................................................................................................... ................................................................................................................. ().................................................................................................................. .............................................................................................................. .............................................. .., .., .., ........................................... ............................. .., ............................................................................................ ..................................................................... .., .., .................................................................. .......................................................................................................... III. ................................................ .., .................................................................................. ...................................................................... .., ............................................................................................. .............................................. .., .., .., .., .......... .................................................................................... .., .., .., .., .., .., .., ............................................................................... .............................................................................. .. .................................................................................................................... Ҳ ϲ ˲Ͳ ...................................................................................................................... .., .., .., . ....................................... в Ҳ ϲ òί ֲ ˲Ͳ ...................................................................................................................... .., .., .., .., .., .., ., ̳ .., .., .., ҳ ......... ϲ ղ̲Ͳ ˲Ͳ ײ ò............................................................................................................. .., .., .., .., .., .., ̳ ..,* .., .., .., ֳ .., ..,* ..,* ..*......................................................... IJ ˲Ͳ вͲ ......................................................................................... IV. , ................................................ .., ........................................................................................ ˲ֲ ϲ Ͳ в ϲ ϲ . .., ............................................................................................ .............................................................. . ....................................................................................................................... C O - CANDIDA ALBICANS.................................................................... ..................................................................................................................... ....................................... .., ................................................................................. ................. .., .., .......................................................................... Ͳ ί ϲ Ͳ Ʋ Ͳ ֲ ²IJ ղò Ͳ ² ϲ.. .., .., .., .., .......... ..................................................................................................................... .. *, .. *, .. **...................................................... , - .......................................... . ., . ., . ., . ..................................... .................................................................................................................. .. *, .. **, .. *...................................................... - .

.............. .. *, .. *, .. *, .. **, .. **, .. ***, .. ***.......................... ( )........................................................................ .. *, .. *, .. *, .. **, .. **, .. ***, .. ***.......................... ( ) .......................................................................................... .. *, .. *, .. *, .. **, .. **, .. ***, .. ***.......................... ( )......................................................................................................................... .. *, .. *, .. *,......................... .. **, .. **, .. ***, .. ***... - ( )......................................................................................................................... ., .., ..................................................... ............................................................................................................................... .. , .. , .. , .. ............................... ............................................................................. .., .., .. ............................... ............................................................................................................. .. *, .. **, .. *...................................................... -- ........................................................................................... .., .., .............................................................. -600, ................................................................................. V. , .............................. .................................................................................................................... ................. .................................................................................................................... ................................................................................................................ .., .., ............................................................ ........................... .., .., ........................................................... ................................................................................ .., .. 1, ............................................................ ................................ .. *, .. **, .. *............................................................... .................................................................................................................... .. *, .. **, .. *.................................................... ............................................... Ahmed M. Fathi *, M. Nabil Mawsouf**..................................................................... ADJUVANT HYPERBARIC OXYGEN AND OZONE THERAPY IN THE TREATMENT OF CHRONIC LEG AND FOOT ULCERS (PILOT CLINICAL STUDY).......................................................................................................................... .., .., .., ............................. ........................... ., .., .., .., ..

.................................................................................................................. ˲ͲͲ ťί ί ϲ ˲Ͳ Ͳ IJ. .., .., ..................................................... , - .............................. .., .., .., .., ....... .......................................................................................................... .., .., .......................................................... ........................................... .., .., .., .., ........ - ........................ .., .., .., ...................... -Ļ ................................................................ .., .., .., ................ .............................................................................................................................. VI. ......... M. N. Mawsouf *,T. T. Tanbouli **............................................................................. OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C TEN YEARS EXPERIENCE................................................................................................................ ....................................................................................................................... .............................................................................. VII. ................................................................................................... .., .., .., .., ............ ........................................... . .................................................................................................... ............. VIII. - ........................................................................................................ .., ............................................................................................. ...... ..,. ., .., .., .., ............................................................................................................... ........................................... .., .

., ....................................................... .................................................................................................................. .., ., ................................................................... - OG............................. ͻ................................. ............................................................................................................ -60-01............. ................................................................................................ I. ., ..

, , .

, () , - . . (V.Bocci, Ferst international congress, Istambul,2009) . , , , . - .

. 1:10. 5 .

20 0.5 . 0.2 20 .

1,3, 15 /. 2 200 . 20 , 100 /. , 200 300 , 2 . 0.5 1 , 10 . 0.5 0.02, 0.1 0.15 , 1, 3, 10 , . . , 7 2 , 98 12 . . (1 /) - 60 .

(3 / 10 / ) - 120 .

.

, , . . in vitro , , 2 3 / . , , .

, 24 / 8 /. 24 / ( ), 7 . , , , / - .

-100, (A.Scwartz .VIII , .). / , . , , 6 10 , 200 / 20 /, 230 25% .

. ( - 300 , 40 /) , 1.8 . , (Z.Schulz, 5 International congress, Gavana,2005), -45 . .

..1, .. 1, .. 1, .. 1, .. 2, .. - - . .. - , ObuhovaLM@yandex.ru , 3 0,9 % NaCl. , [7], [2], N2- N3- [6]. , .

. - 0,9% . ( Specord -40, Carl Zeiss JENA) : 2,1;

0,9;

0,4;

0,21 /.

3 0,59 / 0,67 /;

0,9% NaCl- 0,55 / 0,66 /, .. . -5.

[1] [5]. [5]. ;

( 4192-82). - ( 3006).

. , , 258 , [4]. , 200 . , , . ~ 2*10-4 %.

, 0,9 % NaCl ( 0,0004%). 0,9% Na Cl (0,55 / 3) 0,004 / ;

0,66 / 0,012 /. ( - 0,67 /). 0,011 / ( 0,66 / (0,05)). , , , , .

N3- , 3=0,67 / - 0,080, /3, 0,05 /3.

6,60,3;

- 7,30,2.

. 3 .

.. [3] , - , Cl3- - ClO3-. , , . , .

3=0,67 / 25 ( 51232-98). , , : , :

NO+NO2+O2;

NO2+O3NO3+O2;

NO2+O3N2O N2O5 :

N2O5 + 2(NH3H2O) = 2NH4NO3 + H2O , .

, , .

, , 0,67 /.

1. .., .. . : ;

1956. 380 .

2. .., .. , . . 2007, 88 (4): 301-3.

3. .., .., .., .. .

. 2008;

82, (12): 2271-6.

4. .., .., .. . :

;

1998. 474c.

5. . . . 2, : ;

1969. 1020 .

6. Puckorius P.R., Hess R.T., editors. Ozon use in cooling water systems- case history of a monitored usage and guidelines for potential application. Proceedings of the Eleventh Ozone World Congress;

1993 Aug 29-Sep 3;

San Francisco, CA, (US);

1993. 111 . (Ozone in water and wastewater treatmen;

vol. 2.).

7. Schultze H. and Schultze-Frohlinde. J. Chem.Soc.Farad. Transt., 1975, 71:

P.1099-106.

.. 1, .. 2, .. 3, .. 4, .. ;

;

" ";

. .. ;

, , , tdyubko@mail.ru . , , .

[1-3]: , , , , (). in vitro , .

. (n = 26), . (n = 7), . () ( ). in vitro , 1:1. -80, 2,0 17 / , b . Wistar (n = 15) -- (). , . - .

() N , .. ( . .. , ). (KCL) [1, 2]. () -35, 7-1045, -13-4, " " () , . ( ). Cary Eclipse (Varian). Lambda 35 (Perkin Elmer). Statgraf.

. , . , , . , in vitro . . , , 0,6 /3. KCL . ( ) . KCL, . , KCL , , . , in vitro (, ), . , , , , , . , 5, -2, - , .

. , , (10-12 ), , . . . , .


5 , .

1. .., .., .., .

// . 2007. 3(26). . 41-47.

2. Dyubko T., Kozin Yu., Roshal A., Sokolik O., Zinchenko V., Krzyminski K. Usage of Chemiluminescence Methods for Researches of Ozonotherapy Influence on Total Antioxidant Activity of Blood Plasma of Patients with a Urogenital Infection Contamination // 10th Conference on Methods and Applications of Fluorescence (9- sept. 2007): Book of abstracts. Salzburg, 2007. P. 308.

3. .., .., .., .., ..

// .- 2005.- 2.- . 81-88.

.., .., .., .., .., ..

:

, Ļ;

. Ļ.

, . : , , , , , , , . .

() , . ( .., 1972).

() , . , - , , .

:

, , , , .

, . , , - .

.

92 (). 68 .

.

: , 23% 0,05, . -, . : 2,0;

5,0 10,0 /.

7, 14 21 . , ( , , ), ( ). .

, , , . : ;

;

.

, . .

7 , , . 14 , , , , 5,0 2,0 /., . 21 . .

10,0 / 2 , .

. . , .

:

- 20 2 + 250 2 + 500 2 ;

- 20 2 + 1 2 + 500 2 ;

- (, ) 400 2 + 250 500 1000 2 + 500 2 .

18-25 . , , , , .

2,5 / 200 , 2 .

( ) ( ). 14-18 , , .

: , 70-80 % 2 ;

40-50 %.

:

1.

.

2.

.

3.

, 2,0 / .

4.

.

5.

, .

: , . , , , , .

.

1. .., . . , . 1985. 213 .

2. .

/ . ... ̄ , 1982. 240 .

3. .., .., .. /

. . , . 29. ., 1991. 249 .

4. .., .. . - : , 1972. 98 c.

5. .., .., .. . , , . , 1993. 181 .

6. .., .., .. // . .


. ̄ 1986, . 18. 135 .

7. .., .., .. . - , 1998.

36 c.

8. . 3. , . .. , 1981. 277 .

9. ( 3- - . - 16-18 . - 1998) . , 1998, 146 .

10. . 3. , . .. , 1981. 277 .

.., .., ..;

.., .., .., ...

-

. Ļ

, () , , , . , , , - .

() , , , . , , , - [1,3,4].

, (), . 1968 .. ..

: () [2,5,6].

(), , . . , , - , .. . [3,6].

, , , , , , , , [3,5,6].

, .

. . , .

:

1. , .. .

2. , . , .. . , . . , , .

3. . , .

4. . , .. . , ;

. , , , , .

.

- , . . , . ( ) .

:

1. , .. - , . , .

2. , , , (u, Zn, , F, S).

, , . , .

() , . , , , . , 10-12 10-11 /. , .

u, Zn- : , , , , , , , , , , . . , .

, , , [2,4,6].

, . , .

, . , , . - , - . , . , . , . . ,

. , , .

, , , , , , , . .

, .

.

. , () .

1. , , [5,6].

2. , .

3. , .

4. . .

, , .

, , , .

- .

.

:

- , , - , - .

, , ;

;

;

[1,2,3].

, , , , .

, : ;

, . [3,4,5].

: , . , , , , .

1. .., . .

, . 1985. 213 .

2. . / .

... ̄ , 1982. 240 .

3. .., .., .. / . . , . 29. ., 1991. 249 .

4. .., .., .. . , , . , 1993. 181 .

5. .., .., .. // . .

. ̄ 1986, . 18. 135 .

6. . 3. , . .. , 1981. 277 .

Schulz Siegfried OZONE/OXYGEN IP IN A PRECLINICAL CANCER STUDY* WITH AN OUTLOOK IN HUMAN-AND VETERINARY MEDICINE (PILOT-RESULTS) AND OTHER PRE-CLINICAL STUDIES IN DISCUSSION TO HUMAN DISEASE ENTITIES University of Marburg, Germany Introduction. The application of relatively large amounts of Ozone/Oxygen into the abdomen of laboratory animals is one useful technique to control possible therapeutic and/or toxicological effects of this gaseous mixture in different animal models with different disease entities. The aim of this study was to test the effects of an intraperitoneally insufflated gas mixture (called O3/O2-pneumoperitoneum) on the survival rate, the growth of the primary tumorus and metastatic spread of the VX auricle cancer in New Zealand White rabbits.

Materials and methods. The first observations with Ozone/Oxygen ip from few rabbits with VX2 cell induced bi-auricular tumors encouraged us for further pre clinical studies with statistical importance.. Altogether 41 male rabbits with an uni lateral auricular tumor were used to show the possible efficiacy of ozone/oxygen vs oxygen and sham animals as control by this method of application (O3/O2-PP).

Ozone/Oxygen was insufflated with the Generator Medozon ip, Herrmann Apparatebau, D-Kleinwallstadt, Germany into anaesthesized animals (Metodomidine/Propofol).The single dosis of Ozone/Oxygen was 80 ml gas volume / kg. The concentration was 50 g ozone in 1 ml of the gas mixture. After repetitive insufflations (x 5 dass) from day 14 to 19 after tue tumor cell inoculation, the total amount of ozone was 4 mg/kg. The period of observation was 90 days.

Results. In group O3/O2 (n = 14 rabbits) there was a survival of 50 % compared to O group (n = 13) with 23.1 % survival and compared to the sham group (n = 14) with only 7.1 % survival. There was a total tumor regression and prevention of metastasis in 6 rabbits from O3/O2 group (42.9 %) compared to 2 from the O2 group (15.4 %) and only 1 from sham treatment (7.1 %). Lmph node palpation, body weight development, hematological and clinical chemistry blood parameters, blood gas analysis and microbiological analyses of infected primary tumours were additionally recorded. Finally, the results of an immune suppression study of the cured 6 rabbits and the necropsy of all animals, e. g. weight of parotid lymph nodes and lung metastases will be presented.

Discussion. These preclinical results showed the efficiacy of Ozone/Oxygen ip on an established animal cancer model (VX2). This method of application, called O3/O2 PP, has been used in other experimental disease entities, known as pre-clinical studies.

More studies with O3/O2 in other experimental cancer models are necessary to justify first therapeutical trials on carefully selected human and veterinary patients with spontaneous tumors. However, there is a great challenge to learn about possible mechanisms after direct application of O3/O2 gas into the body, in comparison to other forms of ozone applications. The ethical aspects and legislation of ozone therapy are based mainly on the results of scientific reseach from laboratory animals.

...1, .., .. 1, .. 2, ... , kontkn@mail.ru . , , . . , , , .

, , , , , , . , - , , . .

: () , , () .



Pages:   || 2 | 3 | 4 | 5 |   ...   | 9 |
 
-  >> 





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .